Geron publishes community oncology chart review presentation on imetelstat in MDS
GERN•Safety findings and treatment discontinuations
Early grade 3-4 cytopenias were reported; cytopenias drove discontinuation in 20% of patients, prompting dose holds or reductions.
Community oncology chart review data on RYTELO in lower-risk MDS
Geron published early real-world community oncology data on RYTELO (imetelstat) use in lower-risk MDS anemia patients.
In 24 evaluable patients, median hemoglobin rose 2.3-2.7 g/dL, with median peak 9.0-9.3 g/dL.
A sensitivity analysis excluding labs within 14 days of transfusion showed a 2.5 g/dL median rise, with median peak 8.9-9.1 g/dL.
Chart-captured ≥8-week transfusion-free intervals were seen in 73.3%, with incomplete documentation flagged as a limitation.
